Negative regulation of Bmi-1 by AMPK and implication in cancer progression

Deqiang Huang, Xiaoling He, Junrong Zou, Pei Guo, Shanshan Jiang, Nonghua Lv, Yuriy O. Alekseyev, Lingyu Luo, Zhijun Luo

Oncotarget · 2015 · 31 citations · 29 references

DOIFull text

Open access

Concepts

Abstract

// Deqiang Huang 1 , Xiaoling He 2, 3 , Junrong Zou 2, 3 , Pei Guo 2, 3 , Shanshan Jiang 2, 3 , Nonghua Lv 1 , Yuriy Alekseyev 4 , Lingyu Luo 1 , Zhijun Luo 3, 5 1 Research Institute of Digestive Diseases, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China 2 Graduate Program, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, P.R. China 3 Institute of Basic Medical Sciences, Nanchang University, Nanchang, Jiangxi, P.R. China 4 Departments of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA 02118, USA 5 Department of Biochemistry, Boston University School of Medicine, Boston, MA 02118, USA Correspondence to: Zhijun Luo, e-mail: zluo@bu.edu Lingyu Luo, e-mail: 15270855639@163.com Keywords: AMPK, Bmi-1, LITAF, cancer progression, miRNA Received: July 24, 2015      Accepted: November 15, 2015      Published: December 23, 2015 ABSTRACT Bmi-1 is a transcriptional regulator that promotes tumor cell self-renewal and epithelial to mesenchymal transition and its upregulation is associated with tumor progression, AMPK is an intracellular fuel-sensing enzyme and plays important roles in tumor cell growth and progression. Thus, the present study aims to examine the regulation of Bmi-1 by AMPK. First, our data revealed that, as compared to adjacent normal tissue, Bmi-1 was highly expressed in gastric cancer, whereas phosphorylation of AMPK (p-AMPK) was reduced. Similar findings were observed in lung adenocarcinomas and appeared that the expression of Bmi-1 was correlated with pathological grades of the cancer, where opposite changes were found in p-AMPK. Second, Metformin, a pharmacological AMPK activator and anti-diabetic drug, or ectopic expression of LKB1, diminished expression of Bmi-1 in cancer cells, an event that was reversed by silencing LKB1. Third, knockdown of LITAF, previously identified as a downstream target of AMPK, upregulated Bmi-1, associated with increased cell viability, colony formation, and migration of cancer cells in vitro . Fourth, metformin increased the abundance of miR-15a, miR-128, miR-192, and miR-194, which was prevented by knockdown of LITAF. Accordingly, transfection of these individual miRNAs downregulated Bmi-1. Altogether, our data for the first time suggest a regulatory axis in cancer cells: AMPK upregulates LITAF, which in turn increases miRNAs, leading to attenuation of Bmi-1 expression.

References

29